Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists for narcolepsy and potentially other sleep-wake disorders. Its lead investigational candidate, cleminorexton (formerly ORX750), is being developed for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. The portfolio also includes clinical- and preclinical-stage assets with potential utility across other neurological, neurodegenerative, and neuropsychiatric conditions. Centessa describes its R&D environment as deconstructed and focused on data-driven decisions led by subject matter experts. The (Senior) Director, Clinical Development will lead strategic and operational execution of the late-stage Orexin Receptor 2 Agonist Program (Program 750), reporting directly to the Associate President, Clinical Development. The role provides clinical development leadership for sleep-wake disorders and broader CNS indications, combining strategic direction with hands-on work at program and trial levels. The position is remote within the US, with occasional travel.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Senior
Education Level
Ph.D. or professional degree